Analyzing CG Oncology (NASDAQ:CGON) & Adhera Therapeutics (OTCMKTS:ATRX)

Adhera Therapeutics (OTCMKTS:ATRX) and CG Oncology (NASDAQ:CGON) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, valuation, profitability, earnings, dividends, analyst recommendations and institutional ownership.

Risk and Volatility

Adhera Therapeutics has a beta of 12.38, meaning that its share price is 1,138% more volatile than the S&P 500. Comparatively, CG Oncology has a beta of 1.17, meaning that its share price is 17% more volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of recent ratings and target prices for Adhera Therapeutics and CG Oncology, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Adhera Therapeutics	0	0	0	0	0.00
CG Oncology	1	2	11	0	2.71

CG Oncology has a consensus target price of $69.00, indicating a potential upside of 12.58%. Given CG Oncology’s stronger consensus rating and higher possible upside, analysts plainly believe CG Oncology is more favorable than Adhera Therapeutics.

Earnings and Valuation

This table compares Adhera Therapeutics and CG Oncology”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Adhera Therapeutics	N/A	N/A	N/A	($1.15)	N/A
CG Oncology	$4.04 million	1,280.87	-$160.99 million	($2.07)	-29.61

Adhera Therapeutics has higher earnings, but lower revenue than CG Oncology. CG Oncology is trading at a lower price-to-earnings ratio than Adhera Therapeutics, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Adhera Therapeutics and CG Oncology’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Adhera Therapeutics	N/A	N/A	N/A
CG Oncology	N/A	-22.87%	-21.82%

Insider & Institutional Ownership

26.6% of CG Oncology shares are owned by institutional investors. 28.2% of Adhera Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

About Adhera Therapeutics

Adhera Therapeutics, Inc., a biotech company, focuses on the discovery, development, and commercialization of small molecule drugs. The company is developing MLR-1019 for the treatment of Parkinson's disease; and MLR -1023 to treat Type 1 diabetes. The company was formerly known as Marina Biotech, Inc. and changed its name to Adhera Therapeutics, Inc. in October 2018. Adhera Therapeutics, Inc. is based in Baton Rouge, Louisiana.

About CG Oncology

CG Oncology, Inc., an oncolytic immunotherapy company, focuses on developing and commercializing backbone bladder-sparing therapeutics for patients with bladder cancer. The company develops BOND-003 for the treatment of high-risk bacillus calmette guerin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) patients; CORE-001 to treat cretostimogene in combination with pembrolizumab in high-risk BCG-unresponsive NMIBC patients; and CORE-002 for the treatment of cretostimogene in combination with the checkpoint inhibitor nivolumab in muscle invasive bladder cancer patients. It also develops PIVOT-006, a cretostimogene monotherapy for intermediate-risk NMIBC following transurethral resection of the bladder tumor; and CORE-008 for treating patients with high-risk NMIBC, including BCG-exposed and BCG-naïve NMIBC patients. CG Oncology, Inc. was formerly known as Cold Genesys, Inc. and changed its name to CG Oncology, Inc. in June 2020. The company was founded in 2010 and is based in Irvine, California.